NCT03486067: Phase 1 - CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in relapsed Multiple Myeloma
NCT03489525: Phase 1: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)
NCT03562169: Phase 3: Ixazomib in Autologous Stem Cell Transplant in RRMM Myeloma XII (ACCoRd)
NCT03430011: Phase 1/2 - Autologous BCMA-specific CAR-T cells JCARH125 in RRMM (EVOLVE)
NCT03601078: Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
NCT03777410: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)
NCT03657251: MMRF CureCloud Research Initiative
IMF - International Myeloma Foundation: Understanding Clinical Trials
NCT03710603: Phase 3 - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM (Perseus) EMN17
16th International Myeloma Workshop: March 1-4, 2017 New Delhi, India
Multiple Myeloma – An Introduction - Cancer.Net
NCT03412565: Phase 2 - Subcutaneous Daratumumab in Combination With Standard MM Regimens - PLEIADES
NCT03757221: Phase 2 - IFM 2018-02 - Ixazomib -Daratumumab Without Dex in Elderly RRMM (IDARA)
How can myeloma patients protect themselves from infections? International Myeloma Foundation
NCT03729804: Phase 3: KRd Versus VRd in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
NCT03672318: Phase 1: Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
NCT03435796: Phase 2/3: Long-Term Follow-up for Participants Treated With Gene-Modified T Cells
NCI National Cancer Institute: Immunotherapy: How the Immune System Fights Cancer
NCT03606577: Phase 2-IFM 2018 - 04 - Quadruplet Induction & Consolidation + Tandem ASCT Hi Risk NDMM
NCT03428373: Phase 2: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM)
NCT03752541: Allogeneic T-cells with Anti-BCMA CAR - BCMA-UCART in RRMM - Chinese study
FDA Approved for RRMM: Elotuzumab (Empliciti) with Pomalidomide and dexamethasone (Pd)
NCT03758417: Phase 2 - LCAR-B38M CAR-T Cells Against BCMA in Chinese relapsed Myeloma (CARTIFAN - 1)